Discovery of Rapivab First New and only Antiviral IV Drug Discovered & Commercialized from Alabama for Treatment of Influenza

Friday, October 9, 2020

Dr. Pravin Kotian, VP, Medicinal Chemistry

Biocryst Pharmaceuticals Inc.

Time: 4:45 PM

Location: Hand 1100


Flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. In US 29 million were infected in 2019-2020 out of which 24,000-62,000 deaths were reported by CDC. Discovery and synthesis of Peramivir (trade name Rapivab) by BioCryst Pharmaceuticals a potent inhibitor of influenza Nueraminidase using Structure guided drug design will be presented.

Click here to view more Seminars